Bioventix PLC - London-based biotechnology company - Says that it had a slow start to the financial year that ended June 30. Says that it registered an improvement in the second half and anticipates that its trading results as a whole will ‘likely’ be significantly ahead of market expectations. Attributes the improvement to a degree of recovery from the pandemic woes it experienced since early 2020. ‘We hope that this recovery will prove to be sustained and long-lasting,’ the company says.

Current stock price: 3,350.00 pence, up 6.4% on Wednesday

12-month change: down 13%

Copyright 2022 Alliance News Limited. All Rights Reserved.